Find Clinical Trial

Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer’s Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study.


← Back
Study Phase

Phase 2

Therapeutic Area

Neuropsychiatric Diseases

IndicationAlzheimer's disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S038093

Active Substance CodeS038093
Protocol CodeCL2-38093-005
EudraCT Code2008-007670-37


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility